acyclovir · Ligand Pharms · NDA 203791
Sitavig
Earliest generic entry, as listed
16 Jun 2030
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8592434.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8592434 | drug product, use U-1460 · sets the listed date | 16 Jun 2030 |
| US 8747896 | drug product, use U-1460 | 3 Jun 2027 |
| US 8791127 | drug product, use U-1460 | 23 Mar 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 203791 · 001 · RLD · discontinued | tablet, buccal | 50MG | 16 Jun 2030 |